By its very nature, advanced non-small cell lung cancer is on the move. As the disease progresses, it becomes very difficult to contain. Conventional treatment is quickly overwhelmed and tumors increasingly metastasize throughout the patient’s body.

 

A heat-shock protein called HSP90 plays a central role in facilitating this aggressive metastatic expansion. The assignment was for an experimental compound with potential to work in combination with current treatments to slow disease momentum by reducing metastatic potential.

 

The communication objective of both these speculative concepts was to position ganetespib as an essential addition to second-line therapy—a new and powerful option that would enable oncologists to do more than simply provide palliative treatment and in fact help them to extend survival and maintain their patient’s quality of life by keeping lung cancer static.